Zim Laboratories Ltd
Zim Laboratories Ltd (ZIMLAB) last traded at ₹124, a market capitalisation of ₹668 crore, on a P/E of 181. Over the past 52 weeks the stock has ranged between ₹59.3 and ₹134. Zim Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹94.18 crore and net profit of ₹-4.02 crore. Figures are as of 25 Aug 2026 and are not real time.
Zim Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Zim Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹94.18 cr, up 31.2% from ₹71.76 cr a year earlier. Net profit was ₹-4.02 cr, down 115.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 92.14 | 96.33 | 109 | 71.76 | 88.71 | 109 | 105 | 94.18 |
| Expenses | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 | 91.73 |
| Operating profit | 9.53 | 11.56 | 14.6 | 4.25 | 5.76 | 12.81 | 7.19 | 2.45 |
| OPM % | 10.34% | 12.00% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.60% |
| Other income | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.7 | 6.16 | 0.99 |
| Interest | 2.89 | 2.73 | 2.91 | 3.3 | 3.16 | 3.43 | 3.31 | 3.64 |
| Depreciation | 5 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.1 | 5.37 |
| Profit before tax | 2.96 | 5.7 | 8.11 | -2.43 | -0.34 | 6.05 | 4.94 | -5.57 |
| Tax % | 19.59% | 30.00% | 39.70% | -22.63% | 23.53% | 27.27% | 24.29% | -28.01% |
| Net profit | 2.38 | 4 | 4.88 | -1.87 | -0.42 | 4.4 | 3.74 | -4.02 |
| EPS (₹) | 0.49 | 0.82 | 1.00 | -0.38 | -0.09 | 0.90 | 0.70 | -0.75 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Zim Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 307 | 333 | 399 | 367 | 379 | 374 | 397 |
| Operating profit | 40 | 41 | 52 | 41 | 44 | 30 | 28 |
| OPM % | 13% | 12% | 13% | 11% | 12% | 8% | 7% |
| Net profit | 7 | 15 | 24 | 17 | 12 | 6 | 4 |
| EPS (₹) | 1.50 | 2.99 | 5.01 | 3.54 | 2.50 | 1.09 | 0.76 |
TTM is the trailing twelve months to the most recent quarter.
Zim Laboratories Ltd growth and returns
- 10 Years
- 3%
- 5 Years
- 4%
- 3 Years
- -2%
- TTM
- 8%
- 10 Years
- -7%
- 5 Years
- -17%
- 3 Years
- -44%
- TTM
- -61%
- 10 Years
- %
- 5 Years
- 21%
- 3 Years
- 0%
- 1 Year
- 62%
- 10 Years
- 8%
- 5 Years
- 7%
- 3 Years
- 5%
- Last Year
- 2%
Zim Laboratories Ltd shareholding pattern
Promoters held 30.36% at Jun 2026, down from 33.26% at Jun 2025. FIIs 0.03% and DIIs 1.34%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 30.35% | 30.36% |
| FIIs | 0.00% | 0.21% | 0.01% | 0.03% | 0.00% | 0.02% | 0.00% | 0.03% |
| DIIs | 0.00% | 0.24% | 0.24% | 0.24% | 0.24% | 0.20% | 0.07% | 1.34% |
| Public | 66.73% | 66.29% | 66.49% | 66.46% | 66.52% | 66.52% | 69.57% | 68.28% |
| No. of shareholders | 17,716 | 17,450 | 17,448 | 16,641 | 17,282 | 17,251 | 16,636 | 14,510 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Zim Laboratories Ltd corporate filings
- Transcript of Q1 FY27 Earning Conference callCompany Updatehigh impact
Cruxal's analysis: Zim Laboratories reported Q1 FY27 operating income of INR 94.2 crore, a 31.2% YoY growth…
Read the full analysis - Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotAGM/EGMlow impact
Cruxal's analysis: ZIM Laboratories Limited has successfully concluded a postal ballot process, with…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeCompany Updatelow impact
Cruxal's analysis: Zim Laboratories Limited has formally disclosed the availability of the audio recording…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatehigh impact
Cruxal's analysis: Zim Laboratories Limited reported a consolidated net loss of 4.02 crore for the quarter…
Read the full analysis - Earnings Presentation - Q1 FY27Company Updatehigh impact
Cruxal's analysis: Zim Laboratories Limited reported Q1 FY27 total operating income of 94.2 crore…
Read the full analysis - Board Meeting Outcome for Outcome Of The Board Meeting.Board Meetinghigh impact
Cruxal's analysis: ZIM Laboratories Limited reported a consolidated net loss of 4.02 crore for the quarter…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationCompany Updatelow impact
Cruxal's analysis: ZIM Laboratories Limited has announced an intimation for its Q1FY27 Earnings Conference…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Zim Laboratories Ltd
Cruxal reads every Zim Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.